Swayze Eric, EVP Research, has demonstrated a clear selling bias in recent transactions involving Ionis Pharmaceuticals (IONS), as evidenced by SEC Form 4 filings. Over the course of 54 trades, Eric has sold shares totaling $9,831,803.44, significantly outweighing purchases valued at $4,214,540.57. Notably, Eric has not executed any buy transactions in the most recent period, instead focusing exclusively on sales. Between October 2025 and February 2026, Eric sold shares on 11 occasions, with transactions ranging from $3,722.53 to $1,453,653.26. The largest single sale occurred on January 2, 2026, when Eric disposed of shares worth $1,453,653.26, followed by another substantial sale of $934,661.75 on October 1, 2025. These sales were often accompanied by smaller transactions, such as a $3,722.53 sale on January 16, 2026, and a $3,901.93 sale on October 16, 2025. Additionally, Eric’s activity included several acquisitions and dispositions of derivative securities, primarily stock options, though these transactions did not carry monetary value. The consistent pattern of selling, particularly the absence of recent purchases, suggests a strategic reduction in Eric’s holdings in Ionis Pharmaceuticals. This activity aligns with a broader trend of divestment, as Eric’s total sell value more than doubles his total buy value over the recorded period.
AI-assisted summary